News

September 22, 2015 3:45 pm
  The US Food and Drug Administration (FDA) has agreed for priority review of Amgen’s supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.
September 22, 2015 3:45 pm
  Learn more about how veterans with multiple myeloma deal with the disease and how they navigate the VA and other agencies to optimze their resources.  Sandy Kurtin would also discuss the results of the Veteran's Against Myeloma focus group and...
September 16, 2015 10:00 am
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the...
September 16, 2015 9:45 am
Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma...

Pages